Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older

Yuri Komaki1, Yoshinori Ozono1, Kenichi Nakamura1, Hisayoshi Iwakiri1, Satoru Hasuike1, Mitsue Sueta1, Tadashi Miike1, Shojiro Yamamoto1, Hirofumi Uto2, Kazunori Kusumoto3, Toshimasa Ochiai3, Junya Kato4, Naoto Komada4, Kazuo Kuroki5, Toshiharu Eto5, Masafumi Shigehira6, Shuichi Hirono7, Kenji Nagata1 and Hiroshi Kawakami1*

Abstract

Background: It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the efficacy and safety of glecaprevir and pibrentasvir (G/P) treatment in Japanese patients with HCV infection aged ≥75 years.

Methods: This multicenter, retrospective study included 271 Japanese patients with HCV infection from 12 centers in Miyazaki Prefecture, Japan. Demographic, clinical, virological, and adverse events (AEs) data obtained during and after G/P treatment were collected from medical records. The patients were divided into two groups: younger (n = 199, aged < 75 years) and older (n = 72, aged ≥75 years). Virological data and AEs were analyzed according to the age group.

Results: In intention-to-treat (ITT) and per-protocol analyses, the overall sustained virological response 12 (SVR12) rates were 93% and 98.8%, respectively. Two patients in the older group and 14 patients in the younger group dropped out before SVR12 assessment. Although patients in the older group tended to have liver cirrhosis, 95.8% in the older group and 92% in the younger group achieved SVR12 in the ITT analysis (P = 0.404). In total, 48 (17.7%) patients experienced treatment-related AEs. Common AEs during treatment included pruritus, headache, and fatigue. The AEs were not significantly different between the two groups.

Conclusions: Compared with younger patients, older patients showed similar virological response and tolerance to G/P treatment.

Keywords: Chronic hepatitis C, Direct-acting antivirals, Glecaprevir, Pibrentasvir, Sustained virological response

Background

Hepatitis C virus (HCV) infection is a significant public health concern and a major cause of liver cirrhosis and hepatocellular carcinoma (HCC) [1, 2]. The prevalence of HCV infection in the general population in Japan is estimated to be 0.9% [3], and the age of patients with HCV...
infection is gradually increasing [4]. Interferon (IFN)-based treatment was used to treat HCV infection until 2014. Older patients subjected to IFN-based treatment have poor sustained virological response (SVR) rates and high discontinuation rates due to adverse events (AEs) [5, 6].

In 2014, an IFN-free direct-acting antiviral (DAA) treatment regimen was approved for patients with HCV infection in Japan. IFN-free DAA treatments have demonstrated high efficacy, with an improved safety profile and a treatment duration shorter than IFN-based treatment [7, 8]. Several studies have investigated the efficacy and safety of DAA treatment in older patients [9–11]. In 2017, glecaprevir and pibrentasvir (G/P) treatment was approved in Japan to combat HCV infection. G/P is a once-daily, oral, ribavirin (RBV)-free, pangenotypic, IFN-free DAA treatment used to achieve high rates of SVR12 [12, 13]. In addition, G/P treatment has been reported to have a favorable safety profile in patients with genotype 3–6, prior treatment failure, and severe renal impairment, resulting in the need for hemodialysis [14–20]. Although clinical trials on G/P have included patients aged ≥ 65 years, information on patients aged ≥ 75 years is limited. The Japanese population is aging, and it is estimated that approximately 50% of patients with HCV infection are over 75 years old [21]. However, there are few reports regarding the effect of G/P treatment in patients aged ≥ 75 years. To fill this information gap, in this study we assessed the efficacy and safety of G/P treatment in Japanese patients with HCV infection aged ≥ 75 years.

Methods

Study design and setting

This was a multicenter, retrospective study conducted at 12 centers in the Miyazaki Prefecture, Japan. A total of 271 consecutive patients with HCV infection who underwent G/P treatment between December 2017 and March 2021 were enrolled in the study. Demographic, clinical, virological, and AE data obtained during and after treatment were retrospectively collected from the medical records. Patients with decompensated liver cirrhosis (Child–Pugh grade B or C), patients with HCV genotypes 4–6, and those with active HCC were excluded from the study. The prevalence of HCV genotype 1 infection is approximately 70%, while that of HCV genotype 2 is approximately 20–30% in Japan [22]. Therefore, HCV genotypes 3–6 account for a small proportion of cases. Absence of active HCC was confirmed by ultrasound, computed tomography scan, or magnetic resonance imaging scan before the initiation of G/P treatment. Overall, 199 patients aged < 75 years were allocated to the younger group and 72 patients aged ≥ 75 years were allocated to the older group. Clinical data were analyzed by group. This study was approved by the Research Ethics Committee of the University of Miyazaki. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Treatment regimens

All patients received 300 mg of glecaprevir and 120 mg of pibrentasvir orally once daily for either 8 or 12 weeks depending on the HCV genotype, the presence or absence of liver cirrhosis, and the history of prior treatment with IFN or other DAA regimens. Hepatologists at each facility clinically diagnosed liver cirrhosis based on laboratory tests and imaging findings, including portosystemic shunt, splenomegaly, or esophageal/gastric varices.

Follow-up

All patients underwent both physical examination and laboratory testing, which included measurement of HCV RNA levels at baseline and treatment weeks 4, 8, and 12 for patients with compensated cirrhosis, patients with infected genotype 3, and patients with prior DAA experience) and post-treatment weeks 4, 8, and 12. HCV RNA was measured using the COBAS TaqMan HCV Test (Roche Diagnostics, Tokyo, Japan). The fibrosis-4 (FIB-4) index was calculated before the initiation of G/P treatment. NS5A resistance-associated substitutions (RASs) of HCV were tested by direct sequencing in some patients.

Definition

SVR 12 was defined as undetectable serum HCV RNA levels 12 weeks after the end of treatment. Virological relapse was defined as undetectable HCV RNA levels by the end of treatment and detectable levels during the follow-up period. Non-virological response was defined as continuously detectable HCV RNA levels during treatment.

Statistical analysis

Statistical analysis was performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). Baseline continuous data were expressed as medians, and categorical data were expressed as numbers and percentages. The effectiveness of G/P treatment was evaluated using intention-to-treat (ITT) and per-protocol (PP) analyses. Univariate analyses were performed using χ², Fisher’s exact, or Mann–Whitney U tests. Statistical significance was set at P < 0.05.
Results

Patient characteristics
This study included 271 patients in total, 16 (5.9%) of whom dropped out during or after the end of the treatment; 14 patients failed to present to the hospital after the end of G/P treatment, one patient dropped out due to AEs, and one patient dropped out due to unknown reason. Thus, ITT and PP analyses were performed for 271 and 255 patients, respectively (Fig. 1).

Table 1 shows the characteristics of the 271 patients enrolled in this study. The median age was 65 years (range, 26–88), and 133 of them (49%) were male. In total, 47 patients (17%) were previously treated with IFN-based and/or IFN-free DAA regimens. Only one patient (aged < 75 years) had HCV genotype 3. Of the 42 patients who were tested for HCV NS5A-RASs before treatment, 29 (69%) were positive. The median HCV viral load prior to treatment was 6.2 log IU/mL (range, 2.3–7.6). The prevalence of cirrhosis and FIB-4 index was higher in the older group. Baseline hemoglobin, platelets, alanine aminotransferase (ALT), and estimated glomerular filtration rate (eGFR) were significantly lower in the older group.

Virological response to G/P treatment
The overall SVR12 rates in the ITT and PP analyses were 93% and 98.8%, respectively. The SVR12 rates in the older group were 95.8% and 98.6%, whereas those in the younger group were 92% and 98.9% in the ITT and PP analyses, respectively. The SVR12 rates in the older group were similar to that in the younger group in both analyses.

Figure 2 shows the SVR12 rates according to various clinical and demographic factors. In the ITT analysis, the SVR12 rate of patients with an HCV viral load \( \geq 6 \) log IU/mL was significantly lower than that of patients with an HCV viral load < 6 log IU/mL. The SVR12 rates were not significantly influenced by other parameters, such as gender, HCV genotype, liver status, FIB-4 index, prior HCV treatment, history of HCC, presence of NS5A RASs, and eGFR, in either ITT or PP analysis. Two patients in our study experienced virological relapse (Table 2). One was a 71-year-old woman who underwent Peg-IFN/simeprevir/RBV and daclatasvir/asunaprevir (DCV/ASV) treatment for genotype 1 infection and had NS5A RASs (P32 deletion/Q54H) at baseline. The other patient was a 75-year-old woman who was not tested for NS5A RASs and had no history of prior treatment for genotype 2A infection. One patient in our study experienced a non-virological response. This patient was a 70-year-old woman who had NS5A RASs (S62S/N/T/Y) at baseline and a history of treatment with sofosbuvir/RBV for genotype 2 infection. None of the patients had cirrhosis.
Safety and adverse events

The safety profile for G/P treatment is shown in Table 3. In total, 48 (17.7%) patients experienced treatment-related AEs, but none of them were fatal. The most common AEs during treatment were pruritus, headache, and fatigue, which were found in less than 10% of patients, and at similar rates in the older and younger groups. No AEs were significantly different between the older and younger groups. Four patients discontinued G/P treatment prematurely due to AEs, including pruritus, headache, dyspnea, elevation of ALT, cold like symptoms, and elevation of indirect bilirubin. All of them were in the younger group, and eventually achieved SVR12 (Table 4).

Discussion

In the present study, the overall SVR12 rates in the ITT and PP analyses were 93% and 98.8%, respectively. Those in the older group were 95.8% and 98.6% in the ITT and PP analyses, respectively. There were no significant differences in SVR12 rates between the younger and older groups. Furthermore, there were no significant differences in AEs between the younger and older groups. None of the patients in the older group discontinued G/P treatment due to AEs.

G/P treatment showed a high SVR12 rate in clinical trials [12, 13, 15, 23] and real-world settings [24–26]; however, patients aged ≥ 75 years have typically been under-represented. In Japan, the proportion of undiagnosed HCV carriers is estimated to be highest in the ≥ 75 years age group [27], while it is estimated that approximately 50% of patients with HCV infection are over 75 years old [21]. However, few real-world studies have reported that G/P treatment is highly efficacious and safe in patients aged ≥ 75 years, similar to patients aged < 75 years.

Historically, older patients with HCV have been considered difficult to treat. This is because they have a greater prevalence of advanced liver fibrosis and comorbidities, such as diabetes, hypertension, cardiovascular disease, and severe renal impairment, than younger patients [28, 29]. In the present study, the prevalence of cirrhosis was higher in the older group. Due to the advancement of liver fibrosis, platelet counts, and hemoglobin levels were low and FIB-4 index was significantly higher in the older group. Furthermore, ALT and eGFR were significantly lower in the older group. Akkaya et al. reported a significant inverse correlation between HCV viral load and mean ALT levels, and a positive association between ALT levels and duration of HCV infection [30]. In our study, there was no significant difference in the HCV viral load between the older and younger groups. The older group was considered to have a longer duration of HCV infection than the younger group, but their ALT levels were low. We could not identify a definite cause of low ALT levels; however, a previous report showed a similar result [31].

Table 1 Baseline characteristics of the participants

| Characteristics                  | Total n = 271 | <75 years n = 199 | ≥75 years n = 72 | P value |
|----------------------------------|--------------|------------------|-----------------|---------|
| Male, n (%)                      | 133 (49)     | 107 (54)         | 26 (36)         | 0.010   |
| Age, median (range), years       | 65 (26–88)   | 61 (26–74)       | 78 (75–88)      | <0.001  |
| Cirrhosis, n (%)                 | 55 (19)      | 32 (15)          | 23 (30)         | 0.004   |
| Hemoglobin, median (range), g/dL  | 13.8 (8.2–17.2) | 13.2 (9.2–17.2) | 12.5 (8.2–16.7) | <0.001  |
| Platelets, median (range), × 10^9/L, | 172 (33–386) | 181 (33–386)     | 148 (35–323)    | 0.002   |
| AST, median (range), U/L          | 40 (7–335)   | 39.5 (7–335)     | 42 (17–213)     | 0.516   |
| ALT, median (range), U/L          | 36 (3–493)   | 44 (4–493)       | 32 (3–181)      | 0.004   |
| eGFR, median (range), mL/min/1.73m^2 | 72.6 (3.4–148) | 77.2 (3.4–148) | 61.4 (7.2–104) | <0.001  |
| α-fetoprotein, median (range), ng/mL | 4.1 (0.9–1782) | 4 (0.9–386)     | 4.3 (1.4–1782)  | 0.283   |
| FIB-4 index, median (range)       | 2.6 (0.3–58.4) | 2 (0.3–18)      | 3.9 (1.4–58.4)  | <0.001  |
| FIB-4 index ≥ 3.25, n (%)         | 104 (38)     | 59 (30)          | 45 (63)         | <0.001  |
| HCV RNA, median (range), log_{10} IU/mL | 6.2 (2.3–7.6) | 6.3 (2.3–7.6)   | 6.2 (2.9–7.4)   | 0.361   |
| HCV genotype (G1/G2/G3/unknown)   | 143/123/1/4  | 95/101/1/2       | 48/22/0/2       | 0.044   |
| NSSA RASs present, n (%)          | 29 (69)      | 18 (62)          | 11 (85)         | 0.214   |
| Treatment experienced, n (%)      | 47 (17)      | 33 (17)          | 14 (19)         | 0.583   |
| Previous HCC treatment, n (%)     | 15 (6)       | 9 (5)            | 6 (8)           | 0.362   |

AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4 index, fibrosis-4 index; RASs, resistance-associated substitutions; HCC, hepatocellular carcinoma
Fig. 2 SVR12 rates for each parameter.

(a) age, (b) gender, (c) genotype, (d) HCV viral load, (e) liver status, (f) FIB-4 index, (g) prior HCV treatment, (h) history of HCC, (i) presence of NS5A RASs, (j) eGFR

SVR12, sustained virological response 12 weeks after end of treatment; HCV, hepatitis C virus; FIB-4 index, fibrosis-4 index; HCC, hepatocellular carcinoma; RASs, resistance associated substitutions, eGFR, estimated glomerular filtration rate; ITT, intention-to-treat; PP, per protocol; GT, genotype; CH, chronic hepatitis; LC, liver cirrhosis; treatment-exp, treatment-experienced
Several of our cases showed highly elevated alpha-fetoprotein (AFP). There were 8 patients with AFP ≥ 100 ng/mL in this study, and one patient with the highest AFP (1782 ng/mL) had a history of HCC. Modest elevations of AFP levels (between 10 and 500 ng/mL and occasionally up to 1000 ng/mL) may also be seen in adult patients with hepatitis of any type or liver cirrhosis. The frequency of elevation (> 10 ng/mL) has been reported as around 20%, in chronic hepatitis and as 40% in cirrhosis. These elevations seem to occur either when there is a high degree of inflammatory activity within the liver, or towards the end of an acute hepatitis when the liver function in recovering [32]. For the aforementioned reasons, AFP was considered to be high, despite excluding cases with active HCC.

HCV infection has been associated with an earlier onset of kidney disease and progression to chronic kidney disease [33], which may be a reason for the low eGFR

| Table 2 | Characteristics of patients treated with G/P, who did not achieve sustained virological response |
|---|---|---|---|---|---|---|
| No. | Age | Gender | GT | Liver status | History of HCC | Prior HCV treatment | HCV RNA (log10IU/mL) | NSSA RAS | Treatment duration (weeks) | Outcome |
| 1 | 71 | F | 1 | CH | None | Peg-IFN/SMV/RBV DCV/ASV | 5.8 | P32 deletion/Q54H | 12 | Relapse |
| 2 | 75 | F | 2a | CH | None | None | 6.5 | Unmeasured | 8 | Relapse |
| 3 | 70 | F | 2 | CH | None | SOF/RBV | 6.2 | 5625/N/T/Y | 7 | Non-response |

F, female; GT, genotype; CH, chronic hepatitis; SMV, simeprevir; RBV, ribavirin; DCV, daclatasvir; ASV, asunaprevir; SOF, sofosbuvir

| Table 3 | Summary of adverse events |
|---|---|---|---|---|
| Event, n (%) | Total (n = 271) | <75 years (n = 199) | ≥ 75 years (n = 72) | P value |
| Any AEs | 48 (17.7) | 35 (17.6) | 13 (18.1) | 0.927 |
| Fatal AEs | 0 | 0 | 0 | |
| AEs leading to treatment discontinuation | 4 (1.5) | 4 (2) | 0 | 0.521 |
| Pruritus | 22 (8.1) | 16 (8) | 6 (8.3) | 0.862 |
| Headache | 6 (2.2) | 6 (3) | 0 | 0.306 |
| Fatigue | 4 (1.5) | 3 (1.5) | 1 (1.4) | 0.618 |
| Nausea | 3 (1.1) | 2 (1) | 1 (1.4) | 0.696 |
| Skin eruption | 2 (0.7) | 2 (1) | 0 | 0.959 |
| Palpitation | 1 (0.4) | 1 (0.5) | 0 | 0.959 |
| Abdominal pain | 2 (0.7) | 2 (1) | 0 | 0.959 |
| Sleepiness | 1 (0.4) | 1 (0.5) | 0 | 0.959 |
| Hypertension | 1 (0.4) | 1 (0.5) | 0 | 0.959 |
| Pyelonephritis | 1 (0.4) | 1 (0.5) | 0 | 0.959 |
| Epigastric discomfort | 1 (0.4) | 0 | 1 (1.4) | 0.595 |
| Feverish illness | 1 (0.4) | 0 | 1 (1.4) | 0.595 |
| Head congestion | 1 (0.4) | 0 | 1 (1.4) | 0.595 |
| Cold-like symptoms | 1 (0.4) | 1 (0.5) | 0 | 0.595 |
| Dyspnea | 1 (0.4) | 1 (0.5) | 0 | 0.595 |
| Laboratory abnormalities | 4 (1.5) | 1 (0.5) | 3 (4.2) | 0.101 |
| Elevation of total bilirubin | 1 (0.4) | 1 (0.5) | 0 | 0.959 |
| Elevation of indirect bilirubin | 5 (1.8) | 3 (1.5) | 2 (2.8) | 0.861 |
| Elevation of alkaline phosphatase | 2 (0.7) | 1 (0.5) | 1 (1.3) | 0.960 |
| Elevation of creatinine | 1 (0.4) | 1 (0.5) | 0 | 0.595 |

Data are expressed as number (%)
AEs, adverse events
in the older group. G/P treatment resulted in similarly high SVR12 rates in patients with cirrhosis and severe renal impairment in clinical trials and real-world studies [19, 20, 34]. Likewise, in our study, the SVR12 rates were high, irrespective of liver status and renal impairment.

In our study, the SVR12 rate of patients with an HCV viral load $\geq 6 \log$ IU/mL was significantly lower than that of patients with HCV viral load < $6 \log$ IU/mL only in the ITT analysis. Fifteen out of 169 patients with HCV viral load $\geq 6 \log$ IU/mL and only 1 out of 102 patients with HCV viral load < $6 \log$ IU/mL dropped out of the study. The large number of patients with HCV viral load $\geq 6 \log$ IU/mL resulted in a low SVR12 rate in the ITT analysis.

Two patients experienced virological relapse, and one patient experienced a non-virological response in our study (Table 2). Two of them had NSSA RASs at baseline, and these three patients were infected with genotype 1 or 2. Poordad et al. reported that the SVR12 rates were 79% in cases with past experience with both of NS3/4A protease inhibitor and NSSA inhibitor [35]. A prior Japanese clinical trial showed that G/P treatment is highly effective even for cases with DCV/ASV failure, while the SVR12 rates were 93.9% in patients with prior DAA treatment failure [36]. In the same trial, 30 genotype 1b-infected patients had previously received DCV/ASV. Two of these 30 patients had p32 deletions in NSSA at baseline and both of these patients experienced virological failure [36, 37]. Patient No.1 was considered to be relapsed due to p32 deletion. This patient’s RAS was measured at the initiation of G/P treatment, and the attending physician did not know the result when G/P treatment started.

Chen WM et al. reported that a high viral load ($\geq 10^7$ IU/ml) may predict virological failure in non-cirrhotic patients infected with genotype 2 [38]. The viral load of patient No.2 and No.3 were $< 10^7$ IU/ml, and patient No.3 had no p32 deletion. There were no common factors that were obviously associated with virological failure in these patients.

In our study, five patients discontinued G/P treatment; of these, four discontinued due to AEs, and 1 discontinued due to non-virological response to treatment (Table 4). Four cases achieved SVR12, but one of these four patients achieved SVR12 by changing to ledipasvir/sofosbuvir from G/P treatment. Brown et al. and Zamor et al. reported high adherence to G/P treatment as well as high SVR12 rates in those who were not fully adherent to the G/P treatment [39, 40]. The number of cases is small in this study, and as in the previous reports, the SVR12 rates were considered to be high even if the adherence decreases.

Our study has several limitations. First, this was a retrospective study with a small sample size. Second, NSSA RASs could not be tested in all patients, and a few patients failed to achieve SVR12; therefore, we could not correlate NSSA RASs with treatment failure. Third, due to the multicenter, retrospective study, we were unable to obtain sufficient data on some points, including HCV genotype, AFP, and HCV RNA.

**Conclusion**

G/P treatment resulted in similarly high virological response and had a good tolerance in older and younger patients and might therefore be effective and safe in patients aged $\geq 75$ years.

**Abbreviations**

HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; IFN: Interferon; SVR: Sustained virological response; AEs: Adverse events; DAA: Direct-acting antiviral; G/P: Glecaprevir/pibrentasvir; RBV: Ribavirin; FIB-4: Fibrosis-4; RASs: Resistance-associated substitutions; ITT: Intention-to-treat; PP: Per-protocol; DCV: Daclatasvir; ASV: Asunaprevir; ALT: Alanine aminotransferase; eGFR: Estimated glomerular filtration rate; AFP: Alpha-fetoprotein.

| No. | Age | Gender | GT | Liver status | AEs | Treatment duration (weeks) | Outcome | Characteristics and outcome in patients who discontinued G/P treatment |
|-----|-----|--------|----|--------------|-----|---------------------------|---------|---------------------------------------------------------------------|
| 1   | 62  | M      | 1b | LC           | Pruritus Headache Dyspnea | 2       | SVR | After the discontinuation of G/P treatment, changing to LDV/SOF |
| 2   | 63  | M      | 2  | CH           | Elevation of ALT          | 6       | SVR |                                                   |
| 3   | 72  | F      | 2a | CH           | Headache Cold-like symptoms | 4       | SVR |                                                   |
| 4   | 54  | F      | 2b | LC           | Elevation of Total bilirubin | 8       | SVR |                                                   |
| 5   | 70  | F      | 2  | CH           | Elevation of ALT          | 7       | Non-response |                                                   |

M, male; F, female; GT, genotype; LC, liver cirrhosis; CH, chronic hepatitis; AEs, adverse events; ALT, alanine aminotransferase; G/P, glecaprevir/pibrentasvir; LDV, ledipasvir; SOF, sofosbuvir.
Acknowledgements
Not applicable.

Author contributions
YK designed the study, analyzed data, and wrote the manuscript. YO and
H.K. conceived the study, analyzed data, and revised the manuscript critically.
K.N., H.I., S.H., M.S., T.M., S.Y., H.U., K.K., T.O., J.K., N.K., K.K., T.E., M.S., S.H.
and K.N. collected cases and data. All authors have read and approved the manuscript.

Funding
The funder had no role in the study design, data collection, data analysis, or
results dissemination.

Availability of data and materials
The data analyzed for the current study are not publicly available for ethical
reasons. All data relevant to the study are included in the article. Anonymized
data is available from the corresponding author on request.

Declarations

Ethics approval and consent to participate
This study was approved by the Research Ethics Committee of the University
of Miyazaki. Written informed consent was obtained from all the
study participants.

Consent for publication
Not applicable.

Competing interests
The authors declare that there are no conflicts of interest regarding the publi-
cation of this paper.

Author details
1 Division of Gastroenterology and Hepatology, Department of Internal
   Medicine, National Hospital Organization Miyakonojo Medical Center,
   Miyazaki, Japan. 2 Department of Gastroenterology, Miyazaki Medical Center
   Hospital, Miyazaki, Japan. 3 Department of Internal Medicine, Koga General
   Hospital, Miyazaki, Japan. 4 Department of Gastroenterology and Hepatology,
   Department of Internal Medicine, Faculty of Medicine, University of
   Miyazaki, Miyazaki, Japan. 5 Department of Internal Medicine, Kushima
   Medical Center, Miyazaki, Japan. 6 Department of Internal Medicine, Shige-
hira Clinic, Miyazaki, Japan. 7 Department of Internal Medicine, Hirono Naika
   Clinic, Miyazaki, Japan.

Received: 10 February 2022   Accepted: 14 April 2022
Published online: 28 April 2022

References
1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.
2. Wang LS, D’Souza LS, Jacobson IM. Hepatitis C-A clinical review. J Med Virol. 2016;88:1844–55.
3. Benett H, Waser N, Johnston K, Kao JH, Lim YS, Duan ZP, et al. A review of the
   burden of hepatitis C virus infection in China, Japan, South Korea and
   Taiwan. Hepatol Int. 2015;9:378–90.
4. Tanaka J, Koyama K, Sato H, Sato T, Nakamoto N, Ohishi T, Tsunematsu S, et al. Total
   numbers of undiagnosed carriers of hepatitis C and B viruses in Japan
   estimated by age- and area-specific prevalence on the national scale.
   Intervirology. 2011;54:185–90.
5. Ebinuma H, Saito H, Tada S, Nakamoto N, Ohishi T, Tsunematsu S, et al. Disadvantages of peginterferon and ribavirin treatment in older patients
   with chronic hepatitis C: an analysis using the propensity score. Hepatol Int. 2012;6:744–52.
6. Sato I, Shimbo T, Kawasaki Y, Mizokami M, Masaki N. Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan:
a retrospective study using the Japanese Interferon database. Hepatol Res. 2015;45:829–36.
7. Iio E, Shimada N, Takaguchi K, Senoh T, Eguchi Y, ATSUKAWA M, et al. Clinical
   evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1
   with and without prior daclatasvir/asunaprevir therapy. Hepatol Res. 2017;47:1308–16.
8. Takeuchi Y, Akuta N, Sezaki H, Suzuki F, Fujimura S, KAWAMURA Y, et al. Efficacy and safety of elbasvir plus grazoprevir combination therapy in
   Japanese patients infected with hepatitis C virus genotype 1b. Hepatol Res. 2019;49:256–63.
9. Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype
   1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016;63:1112–9.
10. ATSUKAWA M, TSUBOTA A, KONDO C, SHIMADA N, ABE H, KATO K, et al. Effectiveness and safety of community-based treatment with sofosbuvir
    plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Cid Liver Dis. 2017;49:1029–35.
11. Jhaeri MA, Marine V, Kowdle KV. Chronic hepatitis C in elderly patients: current evidence with direct-acting antivirals. Drugs Aging. 2018;35:117–22.
12. Chayama K, Suzuki F, KARINO Y, KAWAMUKI Y, SATO K, ATARASHI T, et al. Efficacy
    and safety of glecaprevir/pibrentasvir in Japanese patients with chronic
    genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastro-
    troenterol. 2018;53:557–65.
13. Toyoda H, Chayama K, Suzuki F, Sato K, ATARASHI T, Watanabe T, et al. Efficacy and
    safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67:505–13.
14. Zeezarm S, Foster GR, Wang S, Asratyan A, Gane E, Feld JJ, et al. Gle-
    caprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354–69.
15. Brown RS, Buti M, Rodrigues L, Chulanan V, Chuang WL, Aguilar H, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic
    HCV genotypes 1–6 and compensated cirrhosis: the EXPEDI-
    TION-8 trial. J Hepatol. 2020;72:441–9.
16. Asselah T, Kowdle KV, Zadeiks N, Wang S, Hassainie T, Horsmans Y, et al. Efficacy
    of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis
    C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16:417–26.
17. Wyles D, Poordad F, Wang S, Aline L, Felizarta F, Kwo PY, et al. Glecaprevir/
    Pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or
    prior treatment experience: a partially randomized phase 3 clinical trial.
    Hepatology. 2018;67:514–23.
18. Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, et al. Efficacy and
    safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus
    genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multi-
    centre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:45–51.
19. Gane E, Lawitz E, Pugatch D, Papaeteondoris G, Brua N, Brown A, et al. Glecaprevir and
    pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448–55.
20. Lawitz E, Flisikir R, Abunimeh M, Sise ME, Park JY, Kaskas M, et al. Efficacy
    and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic
    HCV infection. Liver Int. 2020;40:1032–41.
21. Karino Y. Innovation in hepatitis C treatment. J Jpn Assoc Rural Med. 2016;65:129–35.
22. Tsukiyama-Kohara K, Kohara M. Hepatitis C virus: viral quasispecies and
    genotypes. Int J Mol Sci. 2018;19:23.
23. Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, et al.
    Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese
    patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. J Gastroenterol Hepatol. 2018;35:117–22.
24. Ogawa E, Furusyo N, Nakamuta M, Nomura H, Satoh T, Takahashi K, et al. Efficacy
    and safety of elbasvir plus grazoprevir combination therapy in Japanese
    patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol. 2019;54:916–27.
25. Liu CH, Liu CJ, Huang CC, Hsieh SM, Su TH, Sun HY, et al. Glecaprevir/
    Pibrentasvir for patients with chronic hepatitis C virus infection: real-
    world effectiveness and safety in Taiwan. Liver Int. 2020;40:758–68.
27. Tanaka J, Akita T, Ohisa M, Sakamune K, Ko K, Uchida S, et al. Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat. 2018;25:363–72.

28. Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother. 2017;18:1867–74.

29. Foster GR, Asselah T, Kopecky-Bromberg S, Leı Y, Asatryan A, Trinh R, et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS ONE. 2019;14: e0208506.

30. Akkaya O, Kiyici M, Yılmaz Y, Uluküye E, Yerci O. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol. 2007;13:5481–5.

31. Watanabe S, Morimoto N, Miura K, Murohisa T, Tahiara T, Sato T, et al. Efficacy and safety of glecaprevir and pibrentasvir combination therapy in old-aged patients with chronic hepatitis C virus infection. J Rural Med. 2020;15:139–45.

32. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145–59.

33. Molnar MZ, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar-Zadeh K, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61:495–502.

34. Yen HH, Su PY, Zeng YH, Liu IL, Huang SP, Hsu YC, et al. Glecaprevir-pibrentasvir for chronic hepatitis C: comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS ONE. 2020;15: e0237582.

35. Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2018;67:1253–60.

36. Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastrointest. 2018;53:566–75.

37. Krishman P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, et al. Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62: e02217.

38. Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, et al. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. J Formos Med Assoc. 2020;119:1593–600.

39. Brown A, Welzel TM, Conway B, Negro F, Bräu N, Grebely J, et al. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials. Liver Int. 2020;40:778–86.

40. Zamor PJ, Brown A, Dylla DE, Dillon JF, Luettelkemeyer AF, Feld JJ, et al. High sustained virologic response rates of glecaprevir/pibrentasvir in patients with dosing interruption or suboptimal adherence. Am J Gastroenterol. 2021;116:1896–904.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions